An Open-Label, Intrapatient Dose Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Biological Activity of ATYR1940 in Patients With Limb Girdle and Facioscapulohumeral Muscular Dystrophies

Trial Profile

An Open-Label, Intrapatient Dose Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Biological Activity of ATYR1940 in Patients With Limb Girdle and Facioscapulohumeral Muscular Dystrophies

Completed
Phase of Trial: Phase I/II

Latest Information Update: 25 Apr 2017

At a glance

  • Drugs ATYR 1940 (Primary)
  • Indications Facioscapulohumeral muscular dystrophy; Limb girdle muscular dystrophies
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors aTyr Pharma
  • Most Recent Events

    • 25 Apr 2017 According to an aTyr Pharma media release, results from this trial were presented at the American Academy of Neurology (AAN) Annual Meeting 2017.
    • 24 Apr 2017 According to an aTyr Pharma media release, results from this trial will be presented at the upcoming American Academy of Neurology (AAN) 69th Annual Meeting.
    • 18 Jan 2017 Results published in the aTyr Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top